N/A N=17 Palliative Strategies in Spinal Cord Injury (SCI)
Spinal Cord Injury
Primary: Muscle Mass Via Dual-Energy X-ray Absortiometry (DEXA)Scan Data — 6104.45; 6355.3 grams — p=.318
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=33 The Effects of Spasticity on Glucose Metabolism in Individuals With Spinal Cord Injury
Spinal Cord Injuries
Primary: Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Insulin Resistance — -0.692; 0.23 correlation coefficient — p=0.006
N/A N=3 Spinal Cord Stimulation in Spinal Muscular Atrophy
Spinal Muscular Atrophy Type 3 · Spinal Muscular Atrophy Type 4
Primary: Muscle Weakness — 2; 3 Participants
N/A N=12 Progressive Strength Training in Spinal Muscular Atrophy
Muscular Atrophy, Spinal
Primary: Strength — 0.39 kilograms
N/A N=53 Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development
Spinal Muscular Atrophy (SMA)
Primary: Motor Function Assessments- Test for Infant Motor Performance Screening Items (TIMPSI) — 36.06; 88.47; 40.54; 89.44 scores on a scale
N/A N=23 Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Knee Osteoarthristis
Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared
Phase 2 N=50 Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)
Kennedy's Disease · Spinal and Bulbar Muscular Atrophy
Primary: Muscle Strength Change From Baseline — -2.2; 3.1; -4.5; 1.3 percent change — p=0.28
N/A N=71 Musculoskeletal Plasticity After Spinal Cord Injury
Spinal Cord Injuries
Primary: Acute Gene Regulation: MSTN — 5.49; 4.76 arbitrary units — p=<0.001
N/A N=33 Novel Intervention to Influence Muscle Plasticity in Veterans
Spinal Cord Injuries
Primary: HF Muscle Force — 23.9; 30.9 Newtons (N)
Phase 1 N=23 Spinal Excitation to Enhance Mobility
Aging
Primary: Walking Speed Change From Baseline — .054; .078; .085; .039 meters/second
N/A N=21 Could Tai-chi Help Maintain Balance of Spinocerebellar Ataxia Patients
Spinocerebellar Ataxias · Tai Chi
Primary: Scale for the Assessment and Rating of Ataxia(SARA) — 11.5; 9 score on a scale
Phase 2 N=37 Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
Spinal and Bulbar Muscular Atrophy
Primary: Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability — 2; 4; 2; 1 Participants
Phase 2 N=94 Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy
Spinal Muscular Atrophy
Primary: Safety Labs
N/A N=38 Strength Training for Skeletal Muscle Adaptation After Stroke
Stroke
Primary: Change in 1-repetition Maximum (RM) Muscle Strength (Leg Press, Paretic Side) — 126.1; 11.3 lbs
Phase 2 N=70 A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
Spinal Muscular Atrophy
Primary: Change From Baseline to Week 8 in Forced Vital Capacity (FVC) — -0.02; -0.03; -0.07 liters — p=0.9086
N/A N=29 Exercise to Reduce Obesity in Spinal Cord Injury
Diabetes Mellitus · Obesity · Paraplegia
Primary: Change in % Body Fat — -1.83; -1.68 Percent Body Fat — p=>0.05
Phase 3 N=22 Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
SMA - Spinal Muscular Atrophy · Gene Therapy
Primary: Achievement of Independent Sitting for at Least 30 Seconds — 13 Participants — p=<0.0001
Phase 3 N=24 Arimoclomol in Sporadic Inclusion Body Myositis
Inclusion Body Myositis
Primary: Count of Adverse Events Reported — 109; 52 adverse events reported
N/A N=18 Spinal Cord Stimulation to Augment Activity Based Therapy
Transcutaneous Spinal Stimulation · Walking · Spasticity
Primary: Change in Walking Function - 10m Walk Walking Speed (m/s) — 0.06; 0.16 speed difference in meters per second
N/A N=21 Multimodal Exercises to Improve Leg Function After Spinal Cord Injury
Spinal Cord Injuries · Paraplegia · Paraparesis
Primary: Change in Motor Evoked Potential (MEP) Amplitude in the Tibialis Anterior Muscle at the End of Training. — -1.75; -2.01 Amplitude percentage of Mmax
Phase 3 N=31 Testosterone Replacement Therapy in Chronic Spinal Cord Injury
Spinal Cord Injury · Hypogonadism
Primary: Dual Energy X-ray Absorptiometry (DXA) Assessment of Lean Tissue Mass (LTM) — 53.1; 50.5 kilograms — p=<0.01
N/A N=36 Spinal Cord Injury Program in Exercise
Spinal Cord Injuries
Primary: Physical Activity Level at Week 8 — 383; 297 Minutes per week
N/A N=21 Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia
Ataxia, Cerebellar · Cerebellar Ataxia · Spinocerebellar Ataxias
Primary: Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline — 53.0; 52.7; 43.0; 52.1 units on a scale — p=<0.001
N/A N=20 FES-Rowing: Preventing the Secondary Conditions of Paralysis Through Vigorous Exercise
Paralysis, Legs
Primary: Barriers to Physical Activity Questionnaire for People With Mobility Impairments (BPAQ-MI) — 0.66; 1.24; 0.22; 0.06 units on a scale
N/A N=37 Forearm Immobilization, Metabolic Health, and Muscle Loss
Healthy
Primary: Percent Change in Forearm Glucose Uptake — -73; 127; -95 Percent change in clamp FGU with immob
N/A N=24 Spinal Cord Injury - Exercise
Spinal Cord Injuries
Primary: Effect of Exercise on Inflammation (C-reactive Protein) — 0.00; 0.05 mg/dL
Phase 2 N=13 Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients
Muscular Atrophy, Spinal
Primary: Hammersmith Functional Motor Scale Expanded (HFMSE) Summary Statistics and Mixed Model Analysis — 0.208; -0.583 Overall Score — p=0.0083
N/A N=40 E-Stim and Achilles Tendon Repair Study
Achilles Tendon Rupture
Primary: Reduce Calf Muscle Atrophy — 859.8; 874.9; 1450.4; 1634.9 mm^2
Phase 1 N=15 Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
Spinal Muscular Atrophy 1
Primary: Number of Participants That Experienced One Grade III or Higher Unanticipated, Treatment-related Toxicity That Presents With Clinical Symptoms and Requires Medical…
N/A N=51 Spinery® A Novel Radio-Frequency Tumor Ablation Device for Spine Metastatic Tumors
Vertebral Metastasis
Primary: Change From Baseline in Worst Pain and Quality of Life Scores at 3 Months Using the Brief Pain Inventory (BPI) and EQ-5D-5L Questionnaires — 3.4; 65.2 points on a…